Guanghui (Gil) Hu

Guanghui (Gil) Hu has been actively involved in the biotechnology industry since 2014. In that year, they began their role as President & CEO and Board Director at Admera Health. Since then, they have held various roles in a number of biotechnology companies, beginning in 2022. At Viva BioInnovator, they are a Venture Partner, at Ribogenics, Inc. they are the Board Chairman & Acting CEO, at Naki Therapeutics they are the Board Director & Interim CEO, at EarlyDiagnostics they are the Interim co-CEO, at WM-Therapeutics they are a Board Director, at Mebias Discovery, Inc. they are a Board Director, at Proviva Therapeutics they are a Board Director, at MorphoGene they are a Board Director, and at Evecxia Therapeutics, Inc. they are a Board Observer.

Guanghui (Gil) Hu attended Tsinghua University from 1987 to 1992, where they earned a BS in Biological Sciences and Biotechnology. Guanghui (Gil) then went on to Baylor College of Medicine from 1995 to 2000 and obtained a PhD in Structural and Computational Biology. In 2005 and 2006, they attended The Wharton School, studying Business.